A previous study showed that 4% (8/200) of all EGFR-mutant NSCLC harbored concurrent ERBB2 amplifications before treatment with TKIs, leading to a shorter PFS compared to patients with EGFR mutations alone (14). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.